Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials (2020)
- Authors:
- USP affiliated authors: SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; ROSSI, GIORDANO NOVAK - FMRP ; ROCHA, JULIANA MENDES - FMRP
- Unidade: FMRP
- DOI: 10.1080/17425255.2020.1754793
- Subjects: CANABINOIDES; INTERAÇÃO DE DROGAS
- Keywords: Cannabidiol; Safety; Serious adverse effects
- Language: Inglês
- Imprenta:
- Source:
- Título: Expert Opinion on Drug Metabolism & Toxicology
- ISSN: 1742-5255
- Volume/Número/Paginação/Ano: v. 16, n. 6, p. 517-526, 2020
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SANTOS, Rafael Guimarães dos et al. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opinion on Drug Metabolism & Toxicology, v. 16, n. 6, p. 517-526, 2020Tradução . . Disponível em: https://doi.org/10.1080/17425255.2020.1754793. Acesso em: 27 dez. 2025. -
APA
Santos, R. G. dos, Guimarães, F. S., Crippa, J. A. de S., Hallak, J. E. C., Rossi, G. N., Rocha, J. M., & Zuardi, A. W. (2020). Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opinion on Drug Metabolism & Toxicology, 16( 6), 517-526. doi:10.1080/17425255.2020.1754793 -
NLM
Santos RG dos, Guimarães FS, Crippa JA de S, Hallak JEC, Rossi GN, Rocha JM, Zuardi AW. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials [Internet]. Expert Opinion on Drug Metabolism & Toxicology. 2020 ; 16( 6): 517-526.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1080/17425255.2020.1754793 -
Vancouver
Santos RG dos, Guimarães FS, Crippa JA de S, Hallak JEC, Rossi GN, Rocha JM, Zuardi AW. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials [Internet]. Expert Opinion on Drug Metabolism & Toxicology. 2020 ; 16( 6): 517-526.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1080/17425255.2020.1754793 - Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
- The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges
- Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: a transcultural study
- The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: a systematic review of randomized controlled trials
- Adverse effects after Ayahuasca administration in the clinical setting [Carta]
- Cannabidiol for the treatment of drug use disorders
- Cannabidiol for the treatment of epilepsy: an overview of possible mechanisms of action and preclinical and human studies
- The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020)
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
Informações sobre o DOI: 10.1080/17425255.2020.1754793 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003016771.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
